Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial

To investigate whether the cardiovascular and renal benefits observed with dapagliflozin in the DECLARE‐TIMI 58 trial are also observed in patients with short and long‐standing diabetes.

[1]  B. Lewis,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD , 2020 .

[2]  F. Cosentino,et al.  The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.

[3]  B. Zinman,et al.  Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups , 2019, Circulation.

[4]  B. Zinman,et al.  Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. , 2019, The New England journal of medicine.

[5]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. , 2019, Circulation.

[6]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[7]  Declare–Timi Investigators.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[8]  Hong-Kyu Lee.  Cardiorenal protective effect of sodium–glucose cotransporter 2 inhibitors and mitochondrial function , 2019, Journal of diabetes investigation.

[9]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[10]  Marc P. Bonaca,et al.  The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial , 2018, American heart journal.

[11]  Deepak L. Bhatt,et al.  DECLARE‐TIMI 58: Participants’ baseline characteristics , 2018, Diabetes, obesity & metabolism.

[12]  J. McMurray,et al.  Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis , 2018, Diabetes, obesity & metabolism.

[13]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[14]  C. Lewis,et al.  Duration of Diabetes and Prediabetes During Adulthood and Subclinical Atherosclerosis and Cardiac Dysfunction in Middle Age: The CARDIA Study , 2018, Diabetes Care.

[15]  D. Yellon,et al.  SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection. , 2017, The lancet. Diabetes & endocrinology.

[16]  Pharmacologic Approaches to Glycemic Treatment : Standards of Medical Care in Diabetes d 2019 , 2018 .

[17]  Lawrence A Leiter,et al.  Glycaemic control and cardiovascular risk factor management in patients with diabetes with and without coronary artery disease: insights from the diabetes mellitus status in Canada survey. , 2016, European heart journal. Quality of care & clinical outcomes.

[18]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[19]  J. Min,et al.  Impact of diabetes duration on the extent and severity of coronary atheroma burden and long-term clinical outcome in asymptomatic type 2 diabetic patients: evaluation by Coronary CT angiography. , 2015, European heart journal cardiovascular Imaging.

[20]  M. Woodward,et al.  Impact of age, age at diagnosis and duration of diabetes on the risk of macrovascular and microvascular complications and death in type 2 diabetes , 2014, Diabetologia.

[21]  S. Garg,et al.  Diabetes duration and the efficacy and safety of insulin glargine versus comparator treatment in patients with type 2 diabetes mellitus. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[22]  Silvio E. Inzucchi,et al.  Personalized Management of Hyperglycemia in Type 2 Diabetes , 2013, Diabetes Care.

[23]  E. Shin,et al.  The impact of diabetes duration on left ventricular diastolic function and cardiovascular disease , 2012, Postgraduate Medical Journal.

[24]  P. Reaven,et al.  Does Aggressive Glycemic Control Benefit Macrovascular and Microvascular Disease in Type 2 Diabetes?: Insights from ACCORD, ADVANCE, and VADT , 2012, Current Cardiology Reports.

[25]  Grant D. Huang,et al.  The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial. , 2011, Journal of diabetes and its complications.

[26]  Peter H Whincup,et al.  Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. , 2011, Archives of internal medicine.

[27]  Richard W Grant,et al.  Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. , 2005, Diabetes care.

[28]  R. D'Agostino,et al.  The significant effect of diabetes duration on coronary heart disease mortality: the Framingham Heart Study. , 2004, Diabetes care.

[29]  S. Saydah,et al.  Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. , 2004, JAMA.